U.S. Markets open in 36 mins.

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.0070.000 (0.000%)
At close: 10:17AM AEST

Genetic Technologies Limited

60-66 Hanover Street
Fitzroy, VIC 3065
61 3 8412 7000

IndustryMedical Laboratories & Research
Full Time Employees

Key Executives

Mr. Eutillio Buccilli CPAChief Exec. Officer & Exec. Director438.88kN/A64
Mr. Kevin Fischer CPA, AGIA, ACIS, B.Com.CFO & Company Sec.146.77kN/AN/A
Dr. Richard Allman Ph.D.Scientific DirectorN/AN/A57
Ms. Diana NewportQuality and Bus. Operations Director114.29kN/A60
Mr. Chris Saunders MBA, B.S.VP of Sales & Marketing - Phenogen Sciences Inc233.67kN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Genetic Technologies Limited operates as a molecular diagnostics company that offers predictive testing and assessment tools to help physicians in managing women’s health. The company’s lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. Genetic Technologies Limited markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Corporate Governance

Genetic Technologies Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.